Healthcare Analysts, along with Dr. David Eichenbaum, discuss the current state and future direction in Geographic Atrophy (GA) (relevant companies APLS, ANNX, BLTE, JNJ, MITO, NVS REGN) on an Analyst/Industry conference call to be held on April 7 at 4:30 pm.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target raised to $31 from $30 at Scotiabank
- Promising Outlook for Apellis Pharmaceuticals: Buy Rating Backed by Key Milestones and Attractive Valuation
- Apellis announces FDA acceptance, priority review of sNDA for EMPAVELI
- Cautious Hold on Apellis Pharmaceuticals Amid Competitive Landscape and Promising Empaveli Prospects
- Morgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli